CD47/MER6
Alpha Lifetech can provide CD47/MER6 corresponding products, help each customer's research and development.
01
Introduction To CD47/MER6
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD47/MER6 protein is a common target in medicine.
CD47 Also known as IAP, MER 6, or OA3, CD47 is a cell surface receptor expressed on healthy cells that is usually overexpressed on cancer cells, to protect cancer cells from phagocytosis by interaction with SIRPα. The CD47 protein consists of a single extracellular Vset IgSF domain, a presenilin domain with five transmembrane parts, and a short cytoplasmic domain subjected to alternative splicing to produce four isoforms. In addition to binding SIRPα and its family member SIRP γ, CD47 interacts with intein and secreted glycoprotein extracellular matrix protein platelet protein-1 (TSP-1). In contrast to the more restricted expression pattern of SIRP α, CD47 is widely expressed in different cell types in vivo, with different expression of CD47 protein isoforms in different tissues.
Function of Target CD47/MER6
A high level of CD47 expression occurs in HCC cells, and if we reduce CD47 in tumor cells, it can have a clear therapeutic effect.CD47 Can bind to the ligand CD172a to prevent macrophages from phagocyting healthy cells, and cancer cells can also use this opportunity to escape the immune system clearance. Some low doses of anti-SIRPα antibodies can block the CD47-SIRPα signaling pathway in tumor cells. At the same time, CD47 binds to the ligand SIRPα, and can also participate in cell-cell adhesion to maintain the structure and function of tissues and organs. The ding of CD47 to SIRPα can transmit inhibitory signals, hinder macrophage phagocytosis and activation of dendritic cells, and then control the immune response.
Gene Pathway of Target CD47/MER6
Under normal conditions, CD47 is expressed on healthy cells such as red blood cells and binds SIRP α on the surface of macrophages to form a CD47-SIRP α signaling complex that prevents these cells from ingestion by macrophages, thus protecting them from misinjury by the immune system.
Signaling in the CD47-SIRP α axis can control the maintenance of erythrocytes, platelets, and HSC and can regulate synaptic cell development in neurons. SIRPα signaling occurs when CD47, Ultimately, this signaling can inhibit macrophage phagocytosis and activation of dendritic cells, thereby controlling the immune response. In addition to the CD47-SIRPα signaling pathway, CD47 may also be involved in the regulation of other signaling pathways. How these signaling pathways affect the body also needs to be explored in depth.
Fig 1: CD47 Gene Pathway. (Reference source: Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα Immune Checkpoint. Immunity. 2020 May 19;52(5):742-752.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD47/MER6 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD47/MER6 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD47/MER6 protein products are also essential. Alpha Lifetech can provide CD47/MER6 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64673 | 50ug,100ug,500ug | |
| ALP64649 | 50ug,100ug,500ug | |
| ALP64623 | 50ug,100ug,500ug | |
| ALP64587 | 50ug,100ug,500ug | |
| ALP64575 | 50ug,100ug,500ug | |
| ALP64559 | 50ug,100ug,500ug | |
| ALP64507 | 50ug,100ug,500ug | |
| ADT1347 | 100ug,1mg,5mg | |
| ADT1354 | 100ug,1mg,5mg | |
| ADT1361 | 100ug,1mg,5mg | |
| ADT1681 | 100ug,1mg,5mg | |
| ADT1381 | 100ug,1mg,5mg | |
Reference
[1] Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα Immune Checkpoint. Immunity. 2020 May 19;52(5):742-752. doi: 10.1016/j.immuni.2020.04.011. PMID: 32433947; PMCID: PMC7340539.
[2] Baba N, Van VQ, Wakahara K, Rubio M, Fortin G, Panzini B, Soucy G, Wassef R, Richard C, Tamaz R, Lahaie R, Bernard EJ, Caussignac Y, Leduc R, Lougnarath R, Bergeron C, Racicot MA, Bergeron F, Panzini MA, Demetter P, Franchimont D, Schäkel K, Weckbecker G, Kolbinger F, Heusser C, Huber T, Welzenbach K, Sarfati M. CD47 fusion protein targets CD172a+ cells in Crohn's disease and dampens the production of IL-1β and TNF. J Exp Med. 2013 Jun 3;210(6):1251-63.
[3] Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPα signaling axis is an innate immune checkpoint in cancer. Immunol Rev. 2017 Mar;276(1):145-164.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102